Workflow
晨光生物(300138):植提稳健增长,业绩持续修复

Investment Rating - The report maintains a "Buy" rating for the company [6][11]. Core Insights - The company reported a revenue of 3.658 billion yuan for the first half of 2025, representing a year-on-year growth of 4.77%, with a net profit of 215 million yuan, up 115.33% year-on-year. The second quarter alone saw a revenue of 1.941 billion yuan, a year-on-year increase of 10.38%, and a net profit of 105 million yuan, up 72.25% year-on-year [4][5]. - The plant extraction business showed significant sales growth, while the cottonseed business turned profitable. The decline in raw material costs positively impacted the profitability of the plant extraction products, leading to a revenue increase of 9.47% and a gross margin improvement of 3.43% [5][6]. - The main products, such as chili red and lutein, experienced substantial sales increases, with chili red sales reaching 6,367 tons (up 43% year-on-year) and lutein sales growing by approximately 22% [5][6]. Financial Summary - The company forecasts earnings per share (EPS) of 0.71 yuan, 0.96 yuan, and 1.12 yuan for the years 2025, 2026, and 2027, respectively [6][7]. - Projected revenues for the years 2024 to 2027 are 6.994 billion yuan, 7.646 billion yuan, 8.231 billion yuan, and 8.809 billion yuan, with growth rates of 1.79%, 9.32%, 7.65%, and 7.02% respectively [7][10]. - The company's net profit is expected to recover significantly, with projections of 345.28 million yuan, 462.05 million yuan, and 539.09 million yuan for the years 2025, 2026, and 2027, respectively [7][10].